Oliceridine Versus Sufentanil on the Incidence of Hypoxemia During Gastrointestinal Endoscopy:A Double-Blind RCT

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is a prospective, single-center, double-blind, randomized controlled trial designed to evaluate the effect of oliceridine versus sufentanil on the incidence of hypoxemia in adult patients undergoing gastrointestinal endoscopy under deep sedation. The trial will compare the rates of hypoxemia (defined as SpO₂ ≤92%) between the two analgesic regimens when combined with propofol. The primary aim is to determine whether oliceridine can reduce the incidence of hypoxemia compared to sufentanil during endoscopic procedures.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:

• Male or female patients aged ≥ 18 years.

• Scheduled to undergo elective gastrointestinal endoscopy (gastroscopy or colonoscopy).

• American Society of Anesthesiologists (ASA) physical status I-III.

• No history of severe cardiopulmonary dysfunction or other major systemic disease.

Locations
Other Locations
China
Tianmen First People's Hospital
RECRUITING
Tianmen
Contact Information
Primary
Shiyou Wei, PhD
lovewishyou@163.com
8615601680288
Time Frame
Start Date: 2025-09-22
Estimated Completion Date: 2025-10-26
Participants
Target number of participants: 508
Treatments
Experimental: Oliceridine Group
Patients in this group will receive intravenous oliceridine (1 mg for gastroscopy or 1.5 mg for colonoscopy) combined with propofol (1-2 mg/kg) for sedation during gastrointestinal endoscopy.
Active_comparator: Sufentanil Group
Patients in this group will receive intravenous sufentanil (5 μg for gastroscopy or 7.5 μg for colonoscopy) combined with propofol (1-2 mg/kg) for sedation during gastrointestinal endoscopy.
Related Therapeutic Areas
Sponsors
Leads: Shiyou Wei

This content was sourced from clinicaltrials.gov